Competitor Analysis: Pseudomonas aeruginosa Vaccines and Therapeutics

Publisher: La Merie Publishing
Pages: 46
Format: PDF
Product Line:
Competitor Analysis
Product Code: LMCA0083
Release Date: May of 2012

300.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Pseudomonas aeruginosa Vaccines & Therapeutics

The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, RNA- and microorganism-based therapies against infection with Pseudomonas aeruginosa as of May 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Pseudomonas aeruginosa is an opportunistic gram-negative bacteria that lives in soil, water, and even in environments like hot tubs. For most healthy people, this bacteria seldom poses a problem. Pseudomonas aeruginosa is much more dangerous to populations who have weak immune systems, the elderly, and those who have been hospitalized for long periods of time. People with cystic fibrosis and with full-blown AIDS frequently die from infections created by the bacteria. Hospital-acquired pneumonia, particularly ventilator-associated pneumonia , causes considerable morbidity and mortality despite antimicrobial therapy and advances in supportive care. It is the second most frequent nosocomial infection and is the major cause of death among hospital-acquired infections.

The report includes a compilation of currently active projects in development of vaccines, antibodies, peptides and small molecules as well as of DNA-, RNA- and microorganism-based therapies targeting Pseudomonas aeruginosa for prophylaxis and treatment of P. aeruginosa infection. In addition, the report lists company-specific R&D pipelines of P. aeruginosa Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Pseudomonas aeruginosa Vaccines & Therapeutics

Index

  • P. aeruginosa Vaccines
  • P. aeruginosa Antibody Therapeutics
  • P. aeruginosa Protein & Peptide Therapeutics
  • P. Aeruginosa DNA, RNA & Microorganism Therapeutics
  • P. Aeruginosa Small Molecule Therapeutics
  • Corporate P. aeruginosa Vaccines & Therapeutics R&D Pipelines
  • About La Merie Publishing



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top